Envista Holdings Corporation (NVST) Stock Price & How to Invest
Last updated November 2026
Short answer
Envista Holdings (NYSE: NVST) is an ordinary US-listed common stock, so shares or fractional shares can be bought at any brokerage, and it also appears inside broad healthcare and small/mid-cap index funds. What the ticker buys is a ~$3.7 billion dental products company (about $23.15 a share on October 16, 2026) on ~$2.86 billion of trailing revenue, roughly two years into a margin repair that has lifted adjusted EBITDA from $296 million in 2024 to a ~$416 million trailing run rate. The shares are up about 7% in 2026 but down about 14% over the past three months, and third-quarter results are due November 4, 2026.
NVST stock price
As of 2026-11-16, Envista Holdings Corporation (NVST) last closed at $24.03, up 25.7% over the past year. Over the past 52 weeks it has traded between $18.95 and $30.26.
Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or Envista Holdings Corporation's investor relations page. Walnut is informational, not investment advice.
NVST key stats
At $24.03 on November 16, 2026, Envista Holdings Corporation (NVST) has a market cap of $3.9B and a P/E of 6.2 on trailing earnings (14.4 on forward earnings). It next reports earnings around February 3, 2027 (estimated).
- Market cap
- $3.9B
- P/E (trailing)
- 6.2
- P/E (forward)
- 14.4
- EPS (trailing 12 months)
- $3.85
- Price to book
- 1.2
- Beta
- 0.94
- Next earnings
- around February 3, 2027 (estimated)
Market cap, P/E and yield are measured at the $24.03 price on November 16, 2026, from Yahoo Finance figures pulled in November 2026. Earnings date from Yahoo Finance. Walnut is informational, not investment advice.
What's new with Envista Holdings Corporation (NVST)?
The last two weeks for Envista Holdings Corporation, as of November 17, 2026: the price move, the next earnings date, what the company filed with the SEC, and what analysts changed.
- NVST closed at $24.03 on November 16, 2026, down 7.5% over the past five trading days (from $25.97).
- Envista Holdings Corporation next reports quarterly results around February 3, 2027 (estimated).
- On November 4, 2026, Envista Holdings Corporation filed its quarterly report (10-Q) with the SEC. Read the 10-Q on sec.gov
- On November 4, 2026, Envista Holdings Corporation filed an 8-K with the SEC reporting quarterly results and information shared with investors (Regulation FD) (Item 2.02, Item 7.01). Read the 8-K on sec.gov
- On November 6, 2026, UBS raised its target to $29.00 from $27.00 (Neutral).
- On November 5, 2026, Evercore ISI Group raised its target to $30.00 from $28.00 (Outperform).
Prices are daily closes from Yahoo Finance. Filings are read from SEC EDGAR every six hours. Analyst actions come from Yahoo Finance as of November 2026. Walnut is informational, not investment advice.
Envista Holdings Corporation (NVST) latest quarter
Envista reported revenue of $692 million for Q3 2026, up 3% from a year earlier (Envista, Nov 4, 2026).
Source: Envista Q3 2026 results, Nov 4, 2026. Full earnings breakdown
What does Envista Holdings Corporation (NVST) do?
Envista Holdings Corporation is a Brea, California dental products maker spun out of Danaher in 2019, selling into more than 130 countries through roughly 30 brands: Nobel Biocare and Implant Direct in implants, Ormco and Spark in orthodontics, DEXIS in imaging, and Kerr in consumables. Two reporting segments carry the business. Specialty Products & Technologies (implants, prosthetics, brackets, aligners, lab products) generated ~$1.75 billion of 2025 sales, while Equipment & Consumables (imaging systems and software, bonding agents, rotary burs, endodontic systems, infection prevention) generated ~$967 million. Around 85% of revenue comes from consumables, services and spare parts rather than capital equipment, which gives the top line a recurring shape even in quarters when dentists defer large purchases. By region, North America contributed ~$1.40 billion of 2025 sales, Western Europe ~$615 million, and emerging markets ~$586 million.
The investment picture is a margin repair now several quarters old. 2024 was the trough: Envista withdrew its full-year guidance, wrote off $1.15 billion of goodwill and intangible assets, and reported a GAAP loss of $6.50 per share. Under CEO Paul Keel, who took the job that year, full-year 2025 produced 6.5% core sales growth, adjusted EBITDA of $372 million (up 26%) and adjusted EPS of $1.19. Momentum carried forward: first-half 2026 sales rose 10.5% to ~$1.44 billion with 7.1% core growth, adjusted EBITDA reached $207 million, and on August 5, 2026 management raised full-year guidance to 3.5% to 4.5% core sales growth and $1.50 to $1.55 in adjusted EPS. A wide gap persists between adjusted and GAAP results, driven mostly by intangible amortization, restructuring charges and an unusually high effective tax rate, so which figure an investor anchors on changes the valuation conclusion substantially.
The stock has not followed the operating numbers in a straight line. Second-quarter 2026 revenue was ~$730.5 million, up 7.1% year over year, and adjusted EPS of $0.41 beat the ~$0.34 consensus, the fourth consecutive quarter above estimates. Even so, shares closed at $23.15 on October 16, 2026, up about 6.7% year to date and about 17% over twelve months, but down about 14% over three months from levels near $27.70 in early August. On October 15, 2026 Baird downgraded the stock to Neutral from Outperform with a $26 price target, while the broader analyst consensus (13 analysts) remains a buy with a mean target near $29.30. Third-quarter results are scheduled for November 4, 2026, with consensus adjusted EPS around $0.36 on about $689 million of revenue.
What's driving Envista Holdings Corporation (NVST)?
1. Margin repair from a low base
Adjusted EBITDA margin moved from 11.8% in 2024 to 13.7% in 2025 and 14.7% in the second quarter of 2026, an expansion management credits to the Envista Business System, a 10% reduction in company-wide G&A, and the Spark aligner business reaching positive operating margin in the second half of 2025. Guidance calls for 11% to 14% adjusted EBITDA growth in 2026 against only 3.5% to 4.5% core sales growth, which implies most of the gain is coming from cost and mix rather than volume. Dental consumables peers operate at meaningfully higher margins, so how much further this can run is the part of the story still unproven.
2. Implants and aligners as the profit pool
Specialty Products & Technologies is 64% of sales and holds the franchises with the strongest pricing and clinical switching costs. Core growth there was 3.1% in the second quarter of 2026, well below the 8.5% posted by Equipment & Consumables, so the higher-margin half of the company is currently the slower-growing half. Nobel Biocare competes at the premium end against Straumann, Implant Direct plays the value tier, and Spark is the challenger to Invisalign in clear aligners.
3. Equipment demand and the imaging cycle
Equipment & Consumables lifted segment operating profit to $45.9 million on $259.5 million of second-quarter 2026 sales, a rebound after a stretch of soft dental practice capital spending. DEXIS imaging systems sit at the discretionary end of that mix and track how willing practice owners are to finance new hardware. Underneath them, restorative materials, endodontics and infection prevention products form a steadier base, part of the roughly 85% of company revenue classified as recurring.
4. Balance sheet and buybacks
Net debt stood near $310 million at the end of the second quarter of 2026 against ~$416 million of trailing adjusted EBITDA, keeping leverage under one turn. On May 5, 2026 the board authorized an additional $300 million repurchase program running through 2029, and the company bought back 2.4 million shares for ~$59 million during the quarter, following $166 million of repurchases in 2025 at an average of roughly $18.06. Envista pays no dividend, so buybacks are the entire shareholder return channel. With the share price near $23 in October 2026, below where most of the 2026 buyback ran, the remaining authorization buys more stock per dollar. One item to track on the calendar: the term loans, the revolving facility and the convertible notes all mature in August 2028, which makes 2027 a refinancing year.
What are the risks to Envista Holdings Corporation (NVST)?
Dental treatment is deferrable, and the 2024 collapse showed how fast patient traffic and practice capital budgets can move against this business. Emerging markets, about 22% of 2025 sales, carry specific pricing pressure: China's volume-based procurement program has forced steep price cuts on dental consumables and implants, and first-half 2026 emerging-market core growth was 0.8% against 8.5% in developed markets. Goodwill and other intangibles still total roughly $3.0 billion on a $5.6 billion balance sheet after the 2024 write-down, so another demand shock could produce a second impairment. Following the April 2024 guidance withdrawal, several plaintiff law firms publicised investigations of potential securities claims; Envista's fiscal 2025 Form 10-K and its second-quarter 2026 Form 10-Q name no securities class action, state that legal proceedings have not materially changed, and carry a $26.3 million accrual covering all litigation matters combined. Roughly half of revenue is earned outside the United States and a single customer accounted for 13% of second-quarter sales, so currency translation and distributor inventory swings can each move reported results independently of underlying demand. Sentiment can also turn faster than fundamentals: the shares fell about 14% in the three months to mid-October 2026 despite a second-quarter beat and raised guidance, and Baird's October 15 downgrade to Neutral is a reminder that the margin repair is now partly priced in. The November 4 third-quarter report will show whether the raised 2026 guidance holds.
What is the Envista Holdings Corporation (NVST) forecast?
13 analysts publish price targets on NVST, averaging $28.92 as of November 2026, or +20.3% against the $24.03 share price on November 16, 2026. The published targets run from $23.00 to $32.00, a moderate spread, and the ratings split 7 buy, 8 hold, 0 sell. Over the last six months there have been 5 raises and 5 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.
Read the full NVST forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.
Is NVST a buy or a sell?
We give no verdict on Envista Holdings Corporation. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.
The case for buying. Margin repair from a low base. Adjusted EBITDA margin moved from 11.8% in 2024 to 13.7% in 2025 and 14.7% in the second quarter of 2026, an expansion management credits to the Envista Business System, a 10% reduction in company-wide G&A, and the Spark aligner business reaching positive operating margin in the second half of 2025. The most optimistic published target, $32.00, assumes this works close to its best case.
The case against. Dental treatment is deferrable, and the 2024 collapse showed how fast patient traffic and practice capital budgets can move against this business. The most pessimistic target, $23.00, is roughly what NVST is worth if this bites instead.
Read the full bull and bear case on NVST, including what would have to change to break either one. Walnut is not an investment adviser.
Has Envista Holdings Corporation (NVST) split its stock?
No. Envista Holdings Corporation (NVST) has not split its stock in the last 10 years. The statement covers only the window we check, so an older split in the company’s history is possible. It also matters less than it once did: fractional shares mean a high price per share no longer keeps smaller investors out, which removed most of the practical reason to split.
How is Envista Holdings Corporation (NVST) valued?
Market cap, P/E and dividend yield at today's price are in the NVST key stats above. The business figures below come from Envista Holdings Corporation's reported results as of October 2026 and change when it next reports.
- Revenue (TTM): ~$2.86 billion; Q2 2026 up 7.1% year over year
- Margins (TTM): ~55% gross, ~10% operating, ~3% net
- Net debt: ~$310 million at the end of Q2 2026, roughly 0.7x adjusted EBITDA
As of October 2026: Two very different multiples describe the same stock: about 40x trailing GAAP earnings, and about 15x the midpoint of management's 2026 adjusted EPS guidance (analysts sit at $1.53 for 2026 and $1.66 for 2027). Bridging them are amortization of acquired intangibles, restructuring charges, and a 2025 effective tax rate near 73% created by US pre-tax losses sitting alongside $203.9 million of international pre-tax income. At roughly 1.3x trailing sales and 1.2x book value after the pullback from August levels, the market is not paying a premium on revenue or assets, the usual shape for a company whose reported earnings lag its operating improvement.
Who competes with Envista Holdings Corporation (NVST)?
Premium implant and orthodontic specialists
Straumann Group (SIX: STMN, which reports in Swiss francs) is the reference point in premium dental implants and competes directly with Nobel Biocare. Align Technology (NASDAQ: ALGN) owns the clear aligner category with Invisalign, against which Envista's Spark is the smaller challenger. ZimVie (NASDAQ: ZIMV) is a pure-play dental implant company after divesting its spine business, and regional value implant makers from South Korea compete hard on price in emerging markets.
Broad-line equipment and consumables makers
Dentsply Sirona (NASDAQ: XRAY) is the closest structural comparison, spanning imaging, treatment centers, consumables and its own implant and aligner lines, and it has worked through its own impairment and turnaround cycle. Solventum (NYSE: SOLV) competes in restorative materials and orthodontic products through its dental solutions business, while privately held imaging specialists such as Planmeca compete against DEXIS on 2D, 3D and intraoral systems.
Distributors that are also the channel
Henry Schein (NASDAQ: HSIC) and the other large dental distributors sit between Envista and most dental practices, which makes them customers and gatekeepers at once. Envista disclosed that its largest customer represented 13% of sales in the second quarter of 2026, up from 11% a year earlier, so distributor purchasing decisions and inventory levels can move quarterly revenue in ways that have little to do with how many procedures dentists actually performed.
What stocks are similar to Envista Holdings Corporation (NVST)?
Other names that sit close to NVST: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. They are useful if you want to spread one thesis across several tickers.
How to invest in Envista Holdings Corporation (NVST)
There are three common ways to get NVST exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so NVST sits alongside other stocks that express the same thesis.
Walnut takes the portfolio route. Describe a thesis where NVST fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.
New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.
The bottom line on Envista Holdings Corporation (NVST)
Envista is a recovery story valued on adjusted numbers, near 15x the midpoint of 2026 adjusted EPS guidance after a roughly 14% pullback since July, where the operating improvement is measurable (four straight quarters of adjusted EPS above consensus) and reported GAAP earnings have not caught up with it.
More on Envista Holdings Corporation (NVST)
Whether NVST is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is NVST a buy or a sell?, and where the stock could go from here in the NVST stock forecast.
For income investors, whether NVST pays a dividend and how the payout looks is covered in does NVST pay a dividend? And to weigh NVST against a peer, read the full side-by-side comparisons: NVST vs ALGN and NVST vs SOLV.
Wondering how NVST fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Your questions about Envista Holdings Corporation
Ask Walnut's AI anything about NVST and see how it fits what you own.
FAQ
What does Envista Holdings actually sell?
+
Dental products, across about 30 brands sold in more than 130 countries. The lineup covers dental implants and prosthetics (Nobel Biocare, Implant Direct), orthodontic brackets and clear aligners (Ormco, Spark), digital imaging systems and software (DEXIS), and everyday clinical consumables such as bonding agents, cements, rotary burs, endodontic systems and infection prevention products (Kerr, Metrex). Roughly 85% of revenue comes from consumables, services and spare parts rather than one-off equipment sales.
How can someone invest in NVST?
+
NVST trades on the New York Stock Exchange as ordinary US common stock, so it can be bought at any US brokerage in whole or fractional shares during regular market hours. It is also held inside broad healthcare sector funds and US small- and mid-cap index funds, which provides indirect exposure without a single-stock position. Within Walnut, it can sit as one constituent of a thematic basket alongside other dental or medical device names, with a target weight set at the basket level.
Is Envista profitable?
+
Yes on both bases in the most recent periods, though the two diverge widely. Trailing twelve-month GAAP net income was about $95 million (~$0.58 diluted per share), while trailing adjusted diluted EPS was about $1.46. Full-year 2025 came in at $47 million of GAAP net income against $202 million of adjusted net income and $372 million of adjusted EBITDA. The 2024 fiscal year was a GAAP loss of $1.12 billion because of a $1.15 billion goodwill and intangible write-down. Second-quarter 2026 GAAP net income was about $53.7 million.
Why did Envista stock fall so heavily in 2024?
+
Envista withdrew its full-year 2024 guidance in the spring of that year after implant and orthodontic demand deteriorated faster than management had forecast, and the stock repriced sharply. Later in 2024 the company recorded $1,153.8 million of goodwill and intangible asset impairments, split between a $960.5 million goodwill charge and a $193.3 million intangible charge, citing weakened global demand, a sustained depressed share price and a higher cost of capital. The 52-week low of $18.77 was set in October 2025, and shares recovered to a 52-week high of about $30.42 before easing back to $23.15 as of October 16, 2026.
Is there an active securities class action against Envista?
+
Envista's fiscal 2025 Form 10-K, filed February 12, 2026, and its second-quarter 2026 Form 10-Q, filed August 5, 2026, name no pending securities class action. Part II, Item 1 of the latest 10-Q states there have been no material changes to legal proceedings, and the litigation note records a $26.3 million accrual covering all legal matters in aggregate. Several plaintiff law firms did publicise investigations of potential claims after the 2024 guidance withdrawal, but an investigation announcement is not a filed complaint. Anyone tracking this should read the litigation note in each new quarterly filing directly.
Does Envista pay a dividend?
+
No. Envista has never declared a common stock dividend, and capital returns run entirely through share repurchases. The board authorized $250 million in February 2025 and an additional $300 million on May 5, 2026 running through 2029. During 2025 the company repurchased 9.2 million shares for about $166 million at an average price near $18.06, and it bought 2.4 million more shares for about $59 million in the second quarter of 2026, leaving roughly $283 million of remaining capacity.
How much debt does Envista carry?
+
Long-term debt was $1,436.3 million as of July 3, 2026, against $1,125.6 million of cash, for net debt of roughly $310 million or about 0.7x trailing adjusted EBITDA. The stack consists of a $428.2 million term loan, a euro-denominated term loan of $399.8 million equivalent, $493.9 million of convertible senior notes and $114.4 million drawn on the revolver. Every one of those instruments matures in August 2028, so refinancing work is likely to surface during 2027.
What is the difference between Envista's two segments?
+
Specialty Products & Technologies covers the high-value clinical franchises: dental implants, regenerative products, prosthetics, orthodontic brackets, aligners, lab products and loupes. It contributed $1,752.8 million of 2025 sales, about 64% of the total. Equipment & Consumables covers everyday clinical supplies plus digital imaging hardware and software, contributing $966.7 million. In the second quarter of 2026 the specialty segment grew core sales 3.1% while equipment and consumables grew 8.5%, an inversion of the usual pattern that is worth watching over the next several quarters.
How did Envista do in its latest quarter?
+
In the second quarter of 2026 (ended July 3), Envista reported revenue of about $730.5 million, up 7.1% year over year, with core sales growth of 3.1% in Specialty Products & Technologies and 8.5% in Equipment & Consumables. Adjusted EPS was $0.41 against a consensus of about $0.34, and GAAP net income was about $53.7 million. Management raised full-year guidance to 3.5% to 4.5% core sales growth and $1.50 to $1.55 of adjusted EPS. Third-quarter results are due November 4, 2026, with consensus adjusted EPS near $0.36.
How has NVST stock performed in 2026?
+
As of October 16, 2026, NVST closed at $23.15, up about 6.7% year to date and about 17% over the past twelve months, but down about 14% over three months. The 52-week range runs from $18.77 to about $30.42. Baird downgraded the shares to Neutral with a $26 target on October 15, 2026, while the 13 analysts in Yahoo Finance's consensus rate the stock a buy with a mean target near $29.30.
Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with Envista Holdings Corporation's investor relations page or your broker before making investment decisions.